Receptor tyrosine kinases (RTKs) and cyclin-dependent kinases (CDKs) are implicated in HCC growth; therefore, they have been used as therapeutic targets for HCC treatment [171]. Here, NTRK1 is linked to hepatocellular carcinoma.